Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Leucine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.39 |
| ▸ | DPP4 | P27487 | 3/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.35 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.35 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL27191662 | 1.00 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| Leucine SCHEMBL17113855 | 1.00 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| Leucine SCHEMBL756553 | 1.00 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| Leucine SCHEMBL29092653 | 1.00 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| Leucine SCHEMBL139231 | 1.00 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| D-Leucine SCHEMBL1537225 | 1.00 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| Leucine SCHEMBL139230 | 1.00 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| Leucine SCHEMBL5060410 | 1.00 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| Leucine SCHEMBL17113857 | 1.00 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| Leucine SCHEMBL8817376 | 0.97 | SLC7A5 (0.51) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111000997-A | Method for treating osteogenesis imperfecta | 建新公司 | 2020-04-14 | — | — | CN | claimed |
| US-10155952-B2 | Method for producing target substance | AJINOMOTO CO., INC. (JP) | 2018-12-18 | — | — | US | claimed |
| US-10024859-B2 | Markers for detection of gastric cancer | PACIFIC EDGE LIMITED (NZ) | 2018-07-17 | — | — | US | claimed |
| US-20170292956-A1 | Markers for Detection of Gastric Cancer | PACIFIC EDGE LIMITED (NZ) | 2017-10-12 | — | — | US | claimed |
| CN-102459646-B | The detection mark of gastric cancer | 环太平洋生物技术有限公司 | 2016-08-10 | — | — | CN | claimed |
| CN-105765067-A | Modified beta-galactosidase | 天野酶株式会社 | 2016-07-13 | — | — | CN | claimed |
| US-9310370-B2 | Markers for detection of gastric cancer | PACIFIC EDGE LIMITED (NZ) | 2016-04-12 | — | — | US | claimed |
| EP-2430193-B1 | MARKERS FOR DETECTION OF GASTRIC CANCER | PACIFIC EDGE LTD (NZ) | 2016-03-09 | — | — | EP | claimed |
| CN-105316405-A | Markers for detection of gastric cancer | PACIFIC EDGE BIOTECHNOLOGY LTD | 2016-02-10 | — | — | CN | claimed |
| EP-2646059-A2 | PROTEASE DEGRADABLE POLYPEPTIDES AND USES THEREOF | The Methodist Hospital System (US) | 2013-10-09 | — | — | EP | claimed |
| EP-2430193-A1 | MARKERS FOR DETECTION OF GASTRIC CANCER | Pacific Edge Biotechnology Limited (NZ) | 2012-03-21 | — | — | EP | claimed |
| WO-2010131984-A1 | MARKERS FOR DETECTION OF GASTRIC CANCER | PACIFIC EDGE BIOTECHNOLOGY LIMITED (NZ) | 2010-11-18 | — | — | WO | claimed |
| US-20090175811-A1 | USE OF COMPOUND THAT INACTIVATES PROTEIN KINASE A IN A COMPOSITION CONTAINING A COSMETICALLY ACCEPTABLE MEDIUM FOR LIGHTENING THE SKIN | SOCIETE D'EXPLOITATION DE PRODUCTS LES INDUSTRIES CHIMIQUES SEPPIC (FR) | 2009-07-09 | — | — | US | claimed |
| EP-1292615-B1 | MODIFIED MORBILLIVIRUS V PROTEINS | WYETH CORP (US) | 2006-10-25 | — | — | EP | claimed |
| US-20050118119-A1 | Use of a compound inactivating the kinase a protein in a composition containg a cosmetically acceptable medium in order to lighten the skin | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES (SEPPIC) (FR) | 2005-06-02 | — | — | US | claimed |
| US-6664066-B2 | Mutant measles virus V protein; gene expression and engineering | WYETH HOLDINGS CORPORATION | 2003-12-16 | — | — | US | claimed |
| US-20030206925-A1 | MODIFIED MORBILLIVIRUS V PROTEINS | WYETH HOLDINGS CORPORATION | 2003-11-06 | — | — | US | claimed |
| EP-0782581-A4 | CLONING OF AN INSULIN-DEPENDENT MEMBRANE AMINOPEPTIDASE FROM GLUT-4 VESICLES | BAYER AG (US) | 2000-05-31 | — | — | EP | claimed |
| EP-0782581-A1 | CLONING OF AN INSULIN-DEPENDENT MEMBRANE AMINOPEPTIDASE FROM GLUT-4 VESICLES | Bayer Corporation (US) | 1997-07-09 | — | — | EP | claimed |
| WO-1996009317-A1 | CLONING OF AN INSULIN-DEPENDENT MEMBRANE AMINOPEPTIDASE FROM GLUT-4 VESICLES | BAYER CORPORATION (US) | 1996-03-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175811-A1 | USE OF COMPOUND THAT INACTIVATES PROTEIN KINASE A IN A COMPOSITION CONTAINING A COSMETICALLY ACCEPTABLE MEDIUM FOR LIGHTENING THE SKIN | PRKACA, PRKACB, PRKACG | SLC7A5 4679/4885SLC1A3 4692/4885SLC1A2 4702/4885 |
| US-20050118119-A1 | Use of a compound inactivating the kinase a protein in a composition containg a cosmetically acceptable medium in order to lighten the skin | PRKACG, PRKACA, PRKACB | SLC7A5 4608/4885SLC1A3 4702/4885SLC1A2 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.